Yes, you can donate blood with hemochromatosis, but only under specific conditions that vary sharply by country. In the United States, the FDA allows people with hereditary hemochromatosis to donate whole blood as a routine volunteer donor, because the condition is not infectious and the risk of iron overload in a recipient is negligible. In the United Kingdom, Canada, and much of Europe, the same person is usually deferred from the public blood supply, though many treatment centers still perform "therapeutic phlebotomy" on-site. The distinction that determines your answer is whether the blood enters the general donor pool or is discarded as medical treatment.
The mechanism: why hemochromatosis blood is both safe and useful
Hereditary hemochromatosis is an inherited disorder of iron regulation, not an infection and not a blood cancer. The most common form, type 1, is driven by HFE gene variants, most often C282Y homozygosity, which cause the body to under-produce the hormone hepcidin. Hepcidin normally blocks iron absorption in the gut. When it is low, dietary iron pours into the bloodstream unchecked and accumulates in the liver, heart, pancreas, and joints.
The blood of a person with hemochromatosis is qualitatively normal. It carries the same red cells, platelets, and clotting factors as anyone else's, and the HFE mutation is not transmissible through transfusion. The excess iron sits largely in tissue stores, not free in the plasma, so a unit of donated blood does not carry a meaningful iron load for a recipient. Per the FDA's 2022 guidance on blood donor eligibility, hereditary hemochromatosis is not itself a disqualifying condition.
The therapeutic logic runs the other way. Removing a unit of whole blood removes roughly 200 to 250 mg of iron bound in hemoglobin. That is why phlebotomy is the first-line treatment, and why the same procedure can serve two purposes at once: lowering the donor's iron burden while supplying a usable unit.
In plain terms: the blood is safe to give, and giving it is also the treatment.
Quantified context: how much iron each donation removes
Understanding the numbers makes the distinction between donation and therapy concrete. A single whole-blood donation in the US is about 500 mL, containing roughly 200 to 250 mg of elemental iron. Maintenance phlebotomy for a patient at target typically removes one unit every 2 to 3 months, which balances ongoing absorption of about 1 mg per day, or 3 to 4 mg per day in someone with the disorder.
The table below compares the volume and iron removed across the main options.
| Procedure | Volume removed | Iron removed per session | Typical interval |
|---|---|---|---|
| Standard whole-blood donation | ~500 mL | 200–250 mg | Every 8 weeks (US minimum) |
| Therapeutic phlebotomy (induction) | ~500 mL | 200–250 mg | Every 1–2 weeks until ferritin <50 ng/mL |
| Therapeutic phlebotomy (maintenance) | ~500 mL | 200–250 mg | Every 2–3 months |
| Red cell apheresis | ~500 mL red cells | Higher per visit | Variable, specialized centers |
The induction phase can require 20 to 40 phlebotomies over 6 to 18 months for a newly diagnosed patient with heavy iron loading. That volume is far beyond what a volunteer donor program permits, which is why treatment and donation are managed separately even when both use the same needle.
Country-by-country rules for donating with hemochromatosis
Eligibility is a patchwork, and the single biggest variable is whether regulators treat hemochromatosis blood as a standard donation or a treatment byproduct. The table and notes below reconcile the thresholds that matter.
- United States: FDA permits donation by people with hereditary hemochromatosis when the blood is labeled and handled per standard donor rules; no special deferral for the condition itself.
- United Kingdom: NHS Blood and Transplant generally defers donors with hemochromatosis from the public supply, though hospital therapeutic phlebotomy continues.
- Canada: Canadian Blood Services typically does not accept donors with the diagnosis for the volunteer supply.
- Australia: Lifeblood generally excludes donors with hemochromatosis from routine donation.
- Much of Europe: rules vary by national blood service, with several countries deferring the diagnosis.
The reconciliation point: a 500 mL unit is a 500 mL unit everywhere, but a US donor at 8-week intervals is a volunteer, while a UK patient at the same interval is receiving a prescription procedure. Same volume, different legal category.
Whole-blood donation vs therapeutic phlebotomy: the real trade-off
The core comparison is not medical but logistical and legal. Both remove the same volume, but they differ in who benefits, who pays, and what happens to the unit.
| Feature | Volunteer whole-blood donation | Therapeutic phlebotomy |
|---|---|---|
| Purpose | Supply the blood bank | Treat iron overload |
| Cost to patient | None | Often billed, USD 0–150 per session |
| Where blood goes | Transfused to patients | Often discarded |
| Frequency limit | Every 8 weeks (US) | As clinically needed |
| Medical supervision | Donor screening only | Physician-ordered, ferritin-guided |
The non-obvious detail: even where donation is allowed, many blood centers will not accept a unit drawn specifically to lower iron unless the donor meets every general criterion, including hemoglobin, weight, and travel history. A patient who is mildly anemic from frequent phlebotomy may be eligible for therapy but not for donation, and those two eligibility tests use different hemoglobin cutoffs.
Common misconceptions and the anemia trap
Several myths persist, and one of them is a genuine safety hazard.
The first misconception is that hemochromatosis blood is "too iron-rich" for recipients. It is not. Transfusion medicine specialists have found no meaningful risk of iron overload from standard units, because the iron is packaged in red cells that the recipient's body processes normally.
The second is that anyone with the diagnosis should simply show up at a blood drive. Many centers screen for the condition and will defer a donor who discloses it, regardless of FDA policy, because center policy can be stricter than the federal minimum.
The third and most dangerous is that more phlebotomy is always better. Aggressive removal can drive hemoglobin and ferritin below safe floors. A ferritin under 50 ng/mL is the usual induction target, but dropping below roughly 20 to 30 ng/mL risks iron-deficiency symptoms. Hemoglobin must stay above the donor threshold, typically 12.5 to 13.0 g/dL depending on sex and center.
Red-flag warnings that mean stop and call your clinician:
- Persistent fatigue, breathlessness, or palpitations after a session.
- Hemoglobin falling below the center's minimum.
- Ferritin dropping below 20 ng/mL.
- New dizziness or fainting at donation.
- Signs of infection at the needle site.
Timeline: what happens from diagnosis to steady state
The time course matters because it explains why the first year looks nothing like later years.
| Phase | Typical duration | Phlebotomy frequency | Goal |
|---|---|---|---|
| Diagnosis and staging | 1–4 weeks | None | Confirm ferritin and genotype |
| Induction | 6–18 months | Every 1–2 weeks | Ferritin <50 ng/mL |
| Transition | 1–3 months | Spacing out | Find maintenance interval |
| Maintenance | Years to lifelong | Every 2–3 months | Ferritin 50–100 ng/mL |
| Monitoring | Ongoing | Labs every 3–6 months | Prevent re-accumulation |
What to actually do if you want to donate
Concrete steps, in order:
- Ask your hematologist whether your ferritin and hemoglobin currently meet donation criteria, not just treatment criteria.
- Call the specific blood center before traveling to a drive; ask whether it accepts donors with hereditary hemochromatosis by name.
- Bring documentation of your genotype and current labs to the screening.
- Never skip a prescribed therapeutic session to "save" a donation for a drive.
- Track ferritin and hemoglobin after each session and report symptoms promptly.
Limitations and what the evidence does not settle
The evidence base is strong on the safety of transfusing hemochromatosis blood and on phlebotomy as effective treatment. What remains unsettled is long-term recipient outcomes at scale, because few registries track iron status in recipients of these units over years. Policy also shifts; the FDA position could be revisited, and national blood services update deferral lists on multi-year cycles. Finally, individual center discretion means the official rule and the person at the desk may disagree. Confirm locally, and treat your clinician's ferritin target as the governing number, not the donor eligibility threshold.